Akin Advises Pharmakon Advisors on Debt Financing for ARCHIMED’s Up to $1.1 Billion Acquisition of Esperion Therapeutics

(New York) –  Akin advised Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry, and the BioPharma Credit funds in connection with a unitranche debt facility to finance the acquisition of Esperion Therapeutics, Inc., a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, by funds managed by ARCHIMED, a leading investment firm focused exclusively on healthcare industries. The transaction is valued at up to approximately $1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones. 

The Akin team was led by tax partner Geoffrey Secol and included fellow tax partners Stuart Leblang and David Snyder, senior counsel Miriam Foley and associates Joshua Elkouby and John Kwack; health care & life sciences partner Kelly Cleary; finance partner Meng Ru; international trade partner Nnedinma Ifudu Nweke; health care & life sciences partner Nate Brown, senior counsel Jo‑Ellyn Klein and associates Jenna Becker and Maddy Bolger; and corporate associates Casey Braden, Ben Sharp, Jake Gawlak and Yossi Abadi. 

For additional information on the transaction, please click here and here.     

Akin is a leading international law firm with more than 1,100 lawyers in offices throughout the United States, Europe, and the Middle East.   

###